Clinical Trial

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Completed
View on ClinicalTrials.gov →
Summary
Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.
Protocol Amendment History 5 changes
critical Trial completed 2026-08-14
notable Enrollment reduced: 470 -> 243 participants 2026-08-14
notable Trial sites expanded: 1 -> 19 locations 2026-08-14
notable Primary completion pushed: 2026-03-31 -> 2026-05-05 2026-08-14
minor Completion pushed: 2026-03-31 -> 2026-05-05 2026-08-14
Trial Details
NCT Number NCT06269120
Lead Sponsor Novo Nordisk A/S
Conditions Type 2 Diabetes
Enrollment 243 participants
Start Date 2024-09-30
Primary Completion 2026-05-05 (estimated)
Study Completion 2026-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-13